ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2022

Abstract Number: 0322

Are Virtual Cognitive Assessments Comparable to In-person Assessments in a Systemic Lupus Erythematosus Cohort?

Michelle Barraclough1, Juan Pablo Diaz-Martinez2, Andrea Knight3, Kathleen Bingham4, Jiandong Su2, Mahta Kakvan2, Carolina Munoz2, Maria Carmela Tartaglia5, Leslet Ruttan6, Joan Wither7, May Choi8, Dennisse Bonilla2, Nicole Anderson2, Simone Appenzeller9, Ben Parker10, Patricia Katz11, Dorcas Beaton12, Robin Green6, Ian N. Bruce13 and Zahi Touma2, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada, 2Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 3The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 4Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, 5University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, 6University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, 7Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, 8Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 9Unicamp, Campinas, São Paulo, Brazil, 10Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, 11UCSF, San Rafael, CA, 12Institute for Work & Health, Toronto, ON, Canada, 13Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2022

Keywords: Cognitive dysfunction, longitudinal studies, Neuropsychological Assessment, Psychometrics

Session Information

Date: Saturday, November 12, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Many in-person research studies, such as ours examining cognitive impairment (CI) in SLE, were paused for safety reasons during the COVID-19 pandemic. To restart the study, cognitive testing originally administered in-person moved to a virtual platform. This required alterations to some tests. This analysis aimed to determine if the administration method (in-person vs virtual) of ACR recommended cognitive tests (ACR-NB) affected participant performance and classification. Participants were also asked if they preferred in-person or virtual assessments.

Methods: Data from our multi-visit, longitudinal, SLE CI study included demographic, clinical and psychiatric characteristics and the modified ACR-NB. Data collection was repeated at 0, 6, 12 and 24 months. The ACR-NB was originally administered in-person (IP), then switched to virtual (V) during the pandemic. Two of the 19 ACR-NB tests could not be administered virtually and three required modification from written to verbal responses for the virtual visits (Table 1). Participant performance across visits was classified as persistently cognitively impaired, fluctuating CI, and non-CI.
Kruskal-Wallis, Mann-Whitney-U or chi-square tests examined group (in-person vs virtual) differences for:
1. Demographic, clinical and psychiatric characteristics (all visits)
2. Cognitive performance (ACR-NB) at:
a. All visits
b. Non-CI group visits only
c. Within person comparison for participants with both an in-person and virtual visit
A retrospective preferences questionnaire was given to participants who completed the ACR-NB both in-person and virtually.

Results: We analysed 328 SLE participants who had 801 visits (696 IP, 105 V). Demographic, clinical and psychiatric characteristics were comparable except the virtual visits had a higher anxiety score (p< 0.001). 10/17 cognitive tests were significantly different for the all visit comparison. For the non-CI visits (394 visits, 346 IP versus 48 V) and within comparisons (n=71), 7/17 cognitive tests were significantly different between virtual and in-person. Across all three comparisons, six tests were consistently statistically significant (Table 2). 12/71 (17%) of participants had a change in CI status due to the seven tests that were significantly different (four now classified with CI and eight no longer classified with CI). 61% of participants completing the preference questionnaire preferred virtual administration.

Conclusion: Of the 19 tests in the ACR-NB, we identified one or more problems with eight (42%) tests as we moved from in-person to virtual administration including: tests that cannot be administered virtually (n=2); tests that required modification (n=3), and tests (n=6) that showed significant and consistent performance differences according to mode of administration. As use of virtual cognitive testing will likely increase due to advances in technology and participant preference, these issues need to be addressed – potentially by validating a virtual version of the ACR-NB. Until then, caution must be taken when directly comparing virtual to in-person testing results. Future studies should avoid using a mixed administration approach.

Supporting image 1

Supporting image 2


Disclosures: M. Barraclough, None; J. Diaz-Martinez, None; A. Knight, None; K. Bingham, None; J. Su, None; M. Kakvan, None; C. Munoz, None; M. Tartaglia, None; L. Ruttan, None; J. Wither, AstraZeneca, Pfizer; M. Choi, AstraZeneca, MitogenDx, mallinckrodt, Janssen, AbbVie/Abbott, Alimentiv, Amgen, AVIR Pharma Inc, BioJAMP, Bristol-Myers Squibb(BMS), Celltrion, Ferring, Fresenius Kabi, McKesson, Mylan, Takeda, Pendopharm, Pfizer, Roche; D. Bonilla, None; N. Anderson, None; S. Appenzeller, None; B. Parker, None; P. Katz, None; D. Beaton, None; R. Green, None; I. Bruce, AstraZeneca, Bristol-Myers Squibb(BMS), Eli Lilly, Aurinia, Janssen, GlaxoSmithKlein(GSK); Z. Touma, None.

To cite this abstract in AMA style:

Barraclough M, Diaz-Martinez J, Knight A, Bingham K, Su J, Kakvan M, Munoz C, Tartaglia M, Ruttan L, Wither J, Choi M, Bonilla D, Anderson N, Appenzeller S, Parker B, Katz P, Beaton D, Green R, Bruce I, Touma Z. Are Virtual Cognitive Assessments Comparable to In-person Assessments in a Systemic Lupus Erythematosus Cohort? [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/are-virtual-cognitive-assessments-comparable-to-in-person-assessments-in-a-systemic-lupus-erythematosus-cohort/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-virtual-cognitive-assessments-comparable-to-in-person-assessments-in-a-systemic-lupus-erythematosus-cohort/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology